Biotech Values

[mcbio]

NKTR has 22 evaluable RCC patients with 0 or 1 prior line of therapy and accrued 11 responses (1 CR) in 22 patients, or 50%.

INCY had 19 evaluable patients with 0 or 1 prior line of therapy* and accrued 9 responses (1 CR) for 47%. I don't have exact breakdown of how many were 0 and how many were 1 prior therapy, but the enrollment ratio was 3:4. FWIW, I'm *very* pessimistic in this indication for epacadostat.

Isn't it also very important to detail the number of patients that were PD-L1 negative? It looks to me like 10 of the RCC patients in NKTR trial were PD-L1 negative. See slide 13 of: http://ir.nektar.com/static-files/dd4fbd52-b125-4c73-8dd4-d07ce4343b05 . What was that figure for the INCY trial?